Search

BioNTech SE ADR

Fermé

SecteurSoins de santé

92.98 0.85

Résumé

Variation du prix de l'action

24h

Actuel

Min

89.88

Max

93.19

Chiffres clés

By Trading Economics

Revenu

-294M

-834M

Ventes

-13M

107M

BPA

-3.03

Marge bénéficiaire

-777.273

Employés

7,807

EBITDA

-32M

-482M

Recommandations

By TipRanks

Recommandations

Achat Fort

Prévisions sur 12 Mois

+33.83% upside

Dividendes

By Acuity

Prochains Résultats

3 nov. 2026

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-17M

23B

Ouverture précédente

92.13

Clôture précédente

92.98

Sentiment de l'Actualité

By Acuity

19%

81%

51 / 340 Classement par Healthcare

BioNTech SE ADR Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

14 août 2026, 19:26 UTC

BioNTech SE shares are higher today, continuing an upward trend since Thursday. This movement occurs despite concerns over declining U.S. retail sales data.

13 août 2026, 19:21 UTC

News

BioNTech SE shares are lower as analysts adjust price targets following a significant second-quarter revenue decline and a net loss of €820.8 million.

12 août 2026, 19:26 UTC

Correlated Moves

BioNTech SE's shares are higher today, supported by a significant rise in Moderna Inc. amid optimistic market sentiment following recent inflation data.

11 août 2026, 20:06 UTC

BioNTech SE shares are near unchanged amid a flat market performance. The stock remains above its 20-day moving average and near the upper end of its one-month range.

10 août 2026, 21:01 UTC

BioNTech SE shares are higher in after-market trading, showing stability despite broader market conditions and weaker-than-expected job growth data.

7 août 2026, 19:56 UTC

News
Correlated Moves

BioNTech SE is trading higher, likely influenced by Moderna's significant gains. The stock remains above its 20-day moving average despite recent revenue declines.

6 août 2026, 19:51 UTC

News
Correlated Moves

BioNTech SE shares are lower amid negative sentiment in the Biotechnology sector, following a revenue decline and CEO transition announcement.

5 août 2026, 19:32 UTC

News

BioNTech SE shares are higher today after Citigroup maintained its Buy rating, lowering its price target to $125 while Evercore ISI kept its Outperform rating at $130.

4 août 2026, 20:03 UTC

News
Social Media

BioNTech SE reported a widened second-quarter loss and lowered 2026 revenue guidance, contributing to shares trading lower since Monday's close.

3 août 2026, 21:01 UTC

BioNTech SE shares are lower in after-market hours, showing little movement despite a broader market rally and investor optimism from lower oil prices.

31 juil. 2026, 19:16 UTC

Correlated Moves

BioNTech SE shares are lower today, pressured by broader market sentiment and a decline in Moderna Inc. The stock remains below its 20-day moving average.

30 juil. 2026, 21:01 UTC

BioNTech SE shares are trading lower in after-market hours, reversing earlier gains and reflecting notable volatility without any specific news to explain the movement.

29 juil. 2026, 19:55 UTC

BioNTech SE shares are advancing during Wednesday's session, reaching a session high earlier today before pulling back slightly. No specific news was identified.

28 juil. 2026, 19:16 UTC

BioNTech SE shares are advancing today, rebounding from earlier lows. The stock's resilience contrasts with declines in the Nikkei 225 Index.

27 juil. 2026, 19:06 UTC

BioNTech SE shares are higher today amid positive market sentiment, reaching a peak earlier. No specific news has been identified to explain the movement.

24 juil. 2026, 19:06 UTC

BioNTech SE shares are lower today, continuing a decline amid broader market pressure and a significant drop in crude oil prices.

22 juil. 2026, 18:06 UTC

BioNTech SE shares are lower today, reflecting broader market caution amid rising crude oil prices and geopolitical tensions ahead of major technology earnings reports.

21 juil. 2026, 14:41 UTC

News

BioNTech SE is rising amid positive market sentiment and plans to report second-quarter 2026 results on August 4, 2026. The Nasdaq 100 Index is also up.

20 juil. 2026, 19:06 UTC

News

BioNTech SE shares are higher today, supported by a positive analyst outlook and an average recommendation of "Moderate Buy" from nineteen brokerage firms.

Comparaison

Variation de prix

BioNTech SE ADR prévision

Objectif de Prix

By TipRanks

33.83% hausse

Prévisions sur 12 Mois

Moyen 124.58 USD  33.83%

Haut 142 USD

Bas 92 USD

Basé sur 12 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

12 ratings

10

Achat

2

Maintien

0

Vente

Sentiment

By Acuity

51 / 340Classement par Soins de santé

Sentiment de l'Actualité

Très Fortes Indications Haussières

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Inférieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos BioNTech SE ADR

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A, as well as strategic partnership the Coalition for Epidemic Preparedness Innovations (CEPI) to strengthen africa's mrna vac
help-icon Live chat